Anti-Mouse CD155 (PVR) [Clone 4.24.1] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse CD155 (PVR) [Clone 4.24.1] — Purified in vivo GOLD™ Functional Grade
Product No.: C2833
Clone 4.24.1 Target CD155 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names PVR (poliovirus receptor) homolog, Clone 4.24 Isotype Rat IgG2a κ Applications B , FC , in vivo |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Isotype Controls Recommended Dilution Buffer Immunogen EL4 transfected with mouse CD155 Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737472 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this 4.24.1 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 4.24.1 recognizes an epitope on mouse CD155. Background CD155 is a transmembrane glycoprotein member of a subfamily of immunoglobulin-like adhesion receptors (nectins). CD155 is commonly known as Poliovirus Receptor (PVR) because of its involvement as a cellular receptor for poliovirus. The normal function of CD155 is to establish intercellular adherens junctions between epithelial cells. Of its 3 extracellular immunoglobulin-like domains (D1, D2, and D3), the virus only recognizes D1. CD155 interacts with both CD226 and CD96 to induce cytotoxicity of NK cells and CTL. The precise role of CD155 in the immune system remains to be elucidated, though it is suspected to be involved in intestinal humoral immune responses. Furthermore, it is thought that CD155 may be used to positively select MHC-independent T cells in the thymus. Antigen Distribution CD155 is expressed at cell junctions on the primary vascular endothelial cells and is highly expressed on DP thymocytes. Ligand/Receptor CD226 (DNAM-1), CD96 Function Apart from its function of adhering junction among contacting epithelial cells, the interaction of DNAM-1 (CD226) with its ligands CD155 and CD112 (nectin 2) induces cytotoxcity of NK cells and CD8+ T cells and cytokine secretion. NCBI Gene Bank ID UniProt.org Research Area Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 4.24.1 is a rat anti-mouse CD155 monoclonal antibody widely used in preclinical research for investigating CD155-mediated immune responses in living mice. This antibody has several important in vivo applications centered around modulating immune checkpoint pathways and tumor immunity. Functional Blockade of CD155 PathwaysResearchers employ clone 4.24.1 primarily for functional blockade or modulation of CD155-mediated pathways in living mice. This includes analyzing immune cell engagement, tumor immunity, and receptor-ligand interactions between CD155 and immune effectors. The antibody effectively disrupts the CD155 signaling axis, which plays crucial roles in both immune activation and suppression. Cancer Immunotherapy ResearchClone 4.24.1 has been extensively used in tumor immunity studies and therapeutic interventions. The antibody has been applied in monitoring tumor burden in mice, particularly in graft-versus-host disease (GVHD) models. Recent studies have utilized this clone in combination therapies, such as with synNotch-programmed iPSC-derived NK cells targeting TIGIT and CD155 pathways. These applications leverage the antibody's ability to block CD155 interactions with inhibitory receptors like TIGIT, potentially enhancing anti-tumor immune responses. Target Recognition and DistributionClone 4.24.1 recognizes a specific epitope on mouse CD155, a transmembrane glycoprotein expressed at cell junctions on primary vascular endothelium. This distribution pattern makes it particularly useful for studying vascular biology and tumor microenvironment interactions. The antibody's high specificity (>95% purity by SDS-PAGE) and low endotoxin levels (≤1.0 EU/mg) make it suitable for sensitive in vivo experiments requiring functional-grade reagents. Experimental AdvantagesThe clone is manufactured using animal-free, in vitro protein-free cell culture techniques and purified through multi-step processes to ensure extremely low endotoxin levels and minimal protein aggregates. These characteristics are essential for in vivo applications where contamination or non-specific effects could confound experimental results. Based on the available information, 4.24.1 is an antibody clone that recognizes mouse CD155 (also known as PVR, or poliovirus receptor). When used in research, particularly in cancer immunology studies, several antibodies and proteins are commonly employed alongside 4.24.1. Common Co-Used Antibodies and Proteins4-1BB agonist antibodies are frequently paired with the 4.24.1 antibody in the literature, especially in cancer research contexts. The 4.24.1 antibody functions as a CD155 targeting agent, and its use in combination with 4-1BB agonists relates to their complementary roles in modulating immune responses. Relevant Interaction PartnersGiven that CD155 serves as a key immune checkpoint molecule, antibodies targeting its natural binding partners are also relevant in experimental contexts: CD226 (DNAM-1) - This is a natural ligand for CD155. The interaction between DNAM-1 and CD155 induces cytotoxicity of NK cells and CD8+ T cells, as well as cytokine secretion. CD96 - Another receptor that interacts with CD155 to regulate NK cell and cytotoxic T lymphocyte (CTL) activity. CD112 (nectin-2) - While not a direct CD155 antibody pairing, CD112 shares functional overlap with CD155 as both serve as ligands for DNAM-1 and participate in similar immune regulatory pathways. These combinations reflect the broader investigation of immune checkpoint pathways and their manipulation for therapeutic purposes, particularly in cancer immunotherapy research where modulating CD155 interactions can affect tumor immunity. Based on the available search results, there is limited information about key findings from clone 4.24.1 citations in scientific literature. However, I can provide what is known about this clone and its applications. Clone 4.24.1 OverviewClone 4.24.1 is a monoclonal antibody that specifically recognizes mouse CD155, also known as Poliovirus Receptor (PVR). This antibody is commonly used in in vivo mouse studies to functionally target CD155. Biological Significance of the TargetCD155 is a transmembrane glycoprotein that belongs to the immunoglobulin-like adhesion receptor subfamily. Beyond its historical identification as the cellular receptor for poliovirus, CD155 plays important roles in immune regulation. The protein establishes intercellular adherens junctions between epithelial cells and interacts with both CD226 and CD96 to induce cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes (CTL). The interaction of CD226 (DNAM-1) with its ligands CD155 and CD112 induces cytotoxicity of NK cells and CD8+ T cells, as well as cytokine secretion. CD155 is expressed at cell junctions on primary vascular endothelial cells and is highly expressed on double-positive (DP) thymocytes. Available CitationOnly one specific citation reference is provided in the search results: Kourepini, E. et al. (2016) published in the Journal of Immunology 196(9):3570-3580. However, the search results do not elaborate on the specific findings from this or other studies using clone 4.24.1. To obtain comprehensive information about key findings from clone 4.24.1 citations, you would need to access specialized citation databases or scientific literature repositories that track the use of this specific antibody clone across published research. Based on the available search results, specific dosing regimens for clone 4.24.1 are not detailed in the provided information. The search results indicate that this clone targets CD155 (PVR) in mice, but comprehensive dosing protocols across different mouse models have not been documented in the sources. General Considerations for In Vivo Antibody DosingWhile specific information about clone 4.24.1 is limited, in vivo antibody dosing in mouse models typically varies based on several factors: Target and mechanism of action significantly influence dosing strategies. For example, checkpoint blockade antibodies like anti-CTLA-4 typically use doses of 100-250 μg per mouse administered intraperitoneally every 3 days. Cell-depleting antibodies such as anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) require 200-250 μg per mouse, administered 2-3 times per week. Mouse strain and model type also affect dosing requirements. As noted for anti-IL-4 antibody (clone 11B11), standard dosing of 1 mg/mouse intraperitoneally every 4-5 days may need adjustment based on the specific mouse strain and tumor model being used. Recommendations for Establishing Dosing ProtocolsWithout published data for clone 4.24.1, researchers would need to establish dosing empirically by:
For precise dosing information specific to clone 4.24.1 across different mouse models, consulting the antibody manufacturer or conducting pilot dose-finding studies would be necessary. References & Citations1. Kourepini, E. et al. (2016) J. Immunol. 196(9):3570-3580. Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-1177 | |
C247 | |
F1175 | |
R1214 | |
S571 |
Formats Available
